Beam Therapeutics (BEAM) Accumulated Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Accumulated Expenses data on file, last reported at $39.3 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $39.3 million, up 29.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.3 million (up 29.96% YoY), and the FY2025 annual result was $29.3 million, up 36.02% from the prior year.
• Accumulated Expenses improved to $39.3 million in Q1 2026 per BEAM's latest filing, from $29.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $111.7 million in Q4 2023 and troughed at $6.8 million in Q1 2022.
• A 5-year average of $36.3 million and a median of $37.5 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses soared 458.96% in 2023, then plunged 80.68% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $49.9 million in 2022, then soared by 123.72% to $111.7 million in 2023, then sank by 80.68% to $21.6 million in 2024, then surged by 36.02% to $29.3 million in 2025, then soared by 33.91% to $39.3 million in 2026.
• Business Quant data shows BEAM's Accumulated Expenses at $39.3 million in Q1 2026, $29.3 million in Q4 2025, and $42.3 million in Q3 2025.